- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02669810
EXCELLENT (EXpanded CELL ENdocardiac Transplantation) (EXCELLENT)
EXpanded CELL ENdocardiac Transplantation (EXCELLENT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Besançon, France, 25030
- CHU BESANCON Hopital Jean Minjoz 3 Boulevard A.Fleming
-
Dijon, France, 21079
- CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel
-
Grenoble, France
- CHU de Grenoble
-
Massy, France
- Institut Jacques Cartier
-
Montpellier, France
- CHU Montpellier Arnaud-De-Villeneuve
-
Mulhouse, France, 68100
- GHRMSA
-
Pessac, France
- Hopital Haut Leveque
-
Toulouse, France
- Hopital de Rangueil
-
-
-
-
-
Dundee, United Kingdom, B15 2GW
- Ninewells Hospital & Medical School
-
Edgbaston, United Kingdom, B15 2GW
- BIRMINGHAM, Queen Elizabeth Hospital ,Mindelsohn Way,
-
Edinburgh, United Kingdom
- University of Edinburgh
-
Leeds, United Kingdom
- Leeds University & Leeds Teaching Hospitals NHS Trust
-
London, United Kingdom, EC1A 7BE
- Saint Bartholomew's Hospital W Smithfield,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- LV main AMI with or without ST segment elevation and with a detection of rise of troponin with at least one value 70 times above the upper reference limit.
- MI within 1 week after first symptoms. D0 = day of last stent implantation or; D0 = day of hospital presentation when no stent implanted.
- Combination of LVEF < 50% and LV akinetic or dyskinetic segment(s) - by echography as per local practice
- Age must be ≥ 18 and ≤ 85 years
- Men and Non-pregnant non-lactating women who take efficacious contraceptive measures such as oral contraceptive medications or efficacious and permanent intra-uterine device (drug eluted or not) (IUD) or subcutaneous permanent contraceptive implants or menopaused women (at least 2 years confirmed menopause) or surgically sterilized women.
- Having previously signed a written informed consent prior to any study-specific procedure
- LVEF remaining < 50% assessed by cMRI at D8 (± 3)
- Identification of LV segment(s) both non-viable (transmural scar extend >50%) and akinetic (no cardiac wall thickening during systole) or dyskinetic (cardiac wall thickening in the wrong orientation during systole) by cMRI at D8 (± 3)
Non-inclusion criteria
- History of CABG surgery
- History of former significant mitral valve replacement surgery or heart transplantation.
- History of severe valve disease: mitral, aortic stenosis / insufficiency.
- History of non-ischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis.
- Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter access to LV.
- Presence of a prosthetic / mechanical aortic or mitral valve or heart constrictive device.
- Sepsis.
- Endocarditis.
- Infectious pericarditis;
- Pericardial tamponade.
- Left Ventricular Thrombus detected at Echo or MRI
- Severe peripheral vascular disease precluding femoral artery access as determined at the time of original catheterization.
- Any condition leading to contraindicated or unexploitable cMRI.
- History of metallic foreign body in their eye
- Former or current aortic dissection
- Previous G-CSF or other hematopoietic growth factor administration.
- Hepatic failure, history of liver cirrhosis or hepatic severe impairment.
- Constitutional or acquired coagulopathy
- Treated chronic renal failure, haemodialysis or renal severe impairment (creatinine clearance < 30 ml/min).
- Prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer or previous cancer in complete response without any treatment in the last 5 years.
- History of prior mediastinal radiation exposure.
- Serious underlying medical condition at the investigator's discretion, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, active autoimmune disease, Amyotrophic Lateral Sclerosis, Systemic Lupus, Multiple Sclerosis).
- Chronic immunomodulatory or cytotoxic drug treatment intake.
- Active bleeding or major surgery within 1 month.
- History or current Human immunodeficiency HIV1-2, HTLV1, HTLV2 (according to 2006/17/EC).
- Current Active Hepatitis B (according to 2006/17/EC) based on the decision of the biologist or/and the PI.
- History or current Hepatitis C (according to 2006/17/EC).
- Syphilis (according to 2006/17/EC) based on the decision of the biologist or/and the P.
- Active participation in any other clinical trials.
- Current or recent treatment (within two months) with another investigational drug or procedure.
- Any other co-existing conditions that will preclude participation in the study or compromise ability to give informed consent.
- Impairment of cognitive function. If patient is 75-85 years old (included), score < 24 at Mini Mental State Examination (MMSE)
- History of Splenomegaly;
- History of Phenylketonuria;
- History of iron-Dextran allergy;
- History of murine protein allergy.
- Diagnosis of Takotsubo
Discontinuation criteria
- Inadequate bone marrow function: patient at risk to have Haemoglobin < 10 g/dL and Platelet count < 100 x 109 /L at the time of blood harvest
- Blood transfusion within the previous 3 days before the first G-CSF injection
- Cardiogenic shock: requirement of i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump) initiated 24 hours before screening cMRI.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard of Care
Patients will be treated as standard treatment for CHF post - AMI.
|
|
Experimental: PROTHERACYTES
The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia). Intracoronary injection will be possible with OTW catheter or microcatheter (UK only) if patient presents a contraindication to intramyocardial injection |
ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Adverse Cardiac Events (MACE)
Time Frame: From randomization up to 6 months
|
The primary endpoint is the incidence of Major Adverse Cardiac Events (MACE), which have been adjudicated and confirmed to be a MACE by an independent and blinded Clinical Events Committee (CEC) from randomization
|
From randomization up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left Ventricle End Systolic Volume index (LVESVi)
Time Frame: From Baseline up to 6 months
|
Improvement of LVESVi will be assessed by comparing cMRI at baseline, 3 and 6 months. The left ventricular volumes will be indexed to body surface area. cMRI will also assess other parameters such as:
|
From Baseline up to 6 months
|
Viability improvement of the infarcted segment(s)
Time Frame: From Baseline up to 6 months
|
The viability assessment will be performed using cMRI and perfusion 99mTc SPECT (optional) respectively.
A correlation assessment between LVESVi improvement and viability of the infarcted segment(s) will be statistically performed.
|
From Baseline up to 6 months
|
Other secondary outcomes measures
Time Frame: From Baseline up to 6 months
|
Cardiac event free survival; Quality of life via SF36 scale
|
From Baseline up to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory outcome measures
Time Frame: From randomization up to 6 months
|
Incidence of adverse events in patient treated via the intracoronary route
|
From randomization up to 6 months
|
Exploratory outcome measures
Time Frame: From randomization up to 6 months
|
Improvement of MACE, of LVESVi, viability of infarcted segments and other cMRI parameters in patient treated with intracoronary route
|
From randomization up to 6 months
|
Exploratory outcome measures
Time Frame: From Baseline up to 6 months
|
cMRI parameters related to microvascular obstruction (MVO) and myocardial perfusion in all patients
|
From Baseline up to 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT 2014-001476-63
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myocardial Infarction
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Jordan Collaborating Cardiology GroupCardiovascular Academy GroupTerminatedTriggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial InfarctionJordan
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Yuan's General HospitalKaohsiung Veterans General Hospital.; Sin-Lau HospitalUnknownAcute Myocardial Infarction, of Inferolateral Wall | Acute Myocardial Infarction, of Inferoposterior WallTaiwan
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Acute Coronary Syndrome | Acute Myocardial Infarction | Metabolic DisturbanceGreece
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Cardio Med Medical CenterGeorge Emil Palade University of Medicine, Pharmacy, Sciences and Technology... and other collaboratorsCompletedAcute Coronary Syndrome | Acute Myocardial Infarction | Systemic Inflammation | Ventricular Remodeling | Non-ST Elevation Myocardial InfarctionRomania
-
Sheba Medical CenterCompletedNon ST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
Clinical Trials on PROTHERACYTES
-
CellProtheraWithdrawnHeart AttackSingapore